BioStem Technologies will participate in the Symposium on Advanced Wound Care Spring meeting in Charlotte, North Carolina, from April 8-12, 2026. The company announced it will highlight its recently introduced Neox Product line, now part of its family of perinatal tissue allografts. This expansion provides physicians with differentiated options depending on clinical need, handling preferences, and site of care requirements.
Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated the company is proud to contribute to the clinical dialogue at SAWC, where wound care professionals, clinicians, and researchers gather. The expanded portfolio offers what the company describes as the most comprehensive suite of placental and umbilical cord tissue solutions, backed by randomized clinical trials and real-world evidence. This participation matters because it represents the ongoing clinical validation of regenerative medicine approaches for wound healing, potentially offering new standards of care for patients with difficult-to-heal wounds.
Beyond exhibit booth hours, BioStem is hosting a lunch symposium titled "A New Season in Wound Care: An Expanded Portfolio Grounded in Evidence" on Thursday, April 9th. The session will feature presentations by Dr. Wendy Weston, PhD, CTBS, William Marston, MD, and Herbert Slade, MD. Discussion topics will include an introduction to the expanded product portfolio, the science behind its birth tissue products, recently published results of a randomized controlled trial on diabetic foot ulcers, and practical guidance on incorporating these therapies into clinical practice. The inclusion of this specific clinical trial data is significant, as diabetic foot ulcers represent a major healthcare challenge with high rates of complications like amputation, and new effective treatments could substantially impact patient outcomes and healthcare costs.
The company will also present a new scientific poster, number LR-020, available for viewing in Exhibit Hall 1C. This demonstrates BioStem's continued investment in clinical research and medical education as it works to expand access to advanced healing technologies. The company's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks and are established in compliance with current Good Tissue Practices and current Good Manufacturing Processes. Its portfolio includes the Neox, Clarix, VENDAJE and American Amnion product lines.
The implications of this showcase are substantial for the wound care industry and patients. The presentation of randomized controlled trial data provides a higher level of evidence for the efficacy of these allograft products, which could influence clinical adoption and insurance coverage decisions. For clinicians, the expanded portfolio with multiple tissue formats offers more tools to address complex wounds in various care settings. For the regenerative medicine field, BioStem's focus on both innovation and clinical evidence reinforces the importance of rigorous science in advancing new therapeutic options. More information about the company is available at https://www.biostemtechnologies.com.
